Pilot Trial of Oral Cabozantinib/XL184 in Metastatic Castrate Resistant Prostate Cancer to Explore the Changes in Bone and Tumor Imaging Related Pathways
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Cabozantinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 11 Feb 2018 Planned End Date changed from 31 Dec 2017 to 30 Jun 2018.
- 11 Feb 2018 Planned primary completion date changed from 31 Dec 2017 to 30 Jun 2018.
- 10 Jun 2017 Biomarkers information updated